聖諾醫藥-B(02257.HK):Sirnaomics推進基於GalAhead™遞送平台的RNAi療法,用於治療補體介導相關疾病
格隆匯8月26日丨聖諾醫藥-B(02257.HK)公佈,公司Sirnaomics正積極推進基於GalAhead™遞送平台的開發,專注於治療補體介導的相關疾病。
Sirnaomics專有的GalNAc-RNAi療法遞送平台GalAhead™依託於獨特的RNA結構,可以"沉默"單個或多個mRNA靶點,特別是其結構中兩個關鍵技術組件mxRNA™(小型化RNAi觸發器)及muRNA™(多單位RNAi觸發器)。補體介導相關疾病是Sirnaomics基於GalAhead遞送平台產品的核心治療領域之一。mxRNA™抑制劑的設計經驗證在齧齒動物和非人類靈長動物模型中具有持久治療活性,基於此公司已經開發三個基於mxRNA™的新項目和一個基於muRNA的項目,並已進入候選治療藥物的提名階段。由於上述候選藥物的結構簡化,故其成藥後的化學、製造和控制過程都具有較好的毒理學特性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.